Update on the treatment of post-menopausal osteoporosis
Update on the treatment of post-menopausal osteoporosis
Background: Osteoporosis has a huge impact on public health, through the increased morbidity, mortality and economic costs associated with resultant fractures. The goal is to evaluate and identify those that are at risk of osteoporotic fracture in order to start preventative and therapeutic measures to reduce their risk of fracture.
Sources of data: This article reviews the data from randomized controlled trials for the current therapeutic agents available in the UK. It also reviews new trial data for promising osteoporosis therapies, in particular Denosumab, a monoclonal antibody against RANK ligand.
Areas of agreement: Bisphosphonates are the current recommended first-line treatments for patients with osteoporosis.
Areas of controversy/growing points: There are a number of patients where bisphosphonates are contraindicated. Under these circumstances, it is important that clinicians have access to alternative treatments. The long-awaited National Institute for Health and Clinical Excellence (NICE) technology appraisals for both primary and secondary prevention and the clinical guidelines will clarify this. Treatment decisions should be based on risk factors and pharmaceutical intervention given to those with the highest risks.
Areas timely for developing research: Future studies are required to look at these agents in combination to see whether anti-fracture efficacy can be improved
health, osteoporosis, review, risk factors, mortality, bone, randomized controlled trials, risk, fractures, nosp, public health, therapy
129-143
Cole, Zoe
6802e58a-59b3-4518-bb7d-6f721732cd61
Dennison, Elaine
ee647287-edb4-4392-8361-e59fd505b1d1
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
June 2008
Cole, Zoe
6802e58a-59b3-4518-bb7d-6f721732cd61
Dennison, Elaine
ee647287-edb4-4392-8361-e59fd505b1d1
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Cole, Zoe, Dennison, Elaine and Cooper, Cyrus
(2008)
Update on the treatment of post-menopausal osteoporosis.
British Medical Bulletin, 86 (1), .
(doi:10.1093/bmb/ldn017).
(PMID:18477578)
Abstract
Background: Osteoporosis has a huge impact on public health, through the increased morbidity, mortality and economic costs associated with resultant fractures. The goal is to evaluate and identify those that are at risk of osteoporotic fracture in order to start preventative and therapeutic measures to reduce their risk of fracture.
Sources of data: This article reviews the data from randomized controlled trials for the current therapeutic agents available in the UK. It also reviews new trial data for promising osteoporosis therapies, in particular Denosumab, a monoclonal antibody against RANK ligand.
Areas of agreement: Bisphosphonates are the current recommended first-line treatments for patients with osteoporosis.
Areas of controversy/growing points: There are a number of patients where bisphosphonates are contraindicated. Under these circumstances, it is important that clinicians have access to alternative treatments. The long-awaited National Institute for Health and Clinical Excellence (NICE) technology appraisals for both primary and secondary prevention and the clinical guidelines will clarify this. Treatment decisions should be based on risk factors and pharmaceutical intervention given to those with the highest risks.
Areas timely for developing research: Future studies are required to look at these agents in combination to see whether anti-fracture efficacy can be improved
This record has no associated files available for download.
More information
Published date: June 2008
Keywords:
health, osteoporosis, review, risk factors, mortality, bone, randomized controlled trials, risk, fractures, nosp, public health, therapy
Identifiers
Local EPrints ID: 70338
URI: http://eprints.soton.ac.uk/id/eprint/70338
ISSN: 0007-1420
PURE UUID: 45b6f671-58a7-4bec-9a2c-517eff4d6dee
Catalogue record
Date deposited: 09 Mar 2010
Last modified: 18 Mar 2024 02:44
Export record
Altmetrics
Contributors
Author:
Zoe Cole
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
